A study recently published in the Journal of the American Medical Directors Association indicates that engaging in moderate physical activity after an evening meal is more effective at controlling postprandial (after-meal) blood glucose levels in people with Type 2 diabetes than engaging in the same activity before the meal…
Read More “Timing Exercise for Maximum Blood Glucose Control”
In a preliminary study out of Ohio State University, two common dietary oils have shown promise as therapies for lowering body fat in certain people with Type 2 diabetes… Read More “Lowering Body Fat: Oils Show Promise for Some”
Medtronic has voluntarily recalled Quick-set infusion sets that have lot numbers beginning with the number 8. A small percentage of these infusion sets, which are used with MiniMed Paradigm insulin pumps, may not work properly… Read More “Infusion Set Recall”
Late last week, results from several European studies showing a possible link between Lantus (insulin glargine) and cancer were published online in the journal Diabetologia. Health agencies such as the U.S. Food and Drug Administration (FDA) and the International Diabetes Federation (IDF) have been swift in their response to the release of this information, indicating that the studies are not conclusive and that people with diabetes should not stop taking Lantus without speaking to their doctors… Read More “Lantus and Cancer: Further Study Needed”
A combination of insulin and vitamin C may help stop diabetes-induced blood vessel damage in people with poor blood glucose control, according to new research published in The Journal of Clinical Endocrinology and Metabolism. Halting this damage could help prevent a host of complications, such as chronic heart failure, kidney disease, and eye disease… Read More “Vitamin C to Prevent Diabetes Damage?”
The Food and Drug Administration (FDA) is advising people who use the long-acting insulin detemir (brand name Levemir) to check their insulin vials to ensure that none are from a potentially dangerous batch that appeared on the U.S. market last week after having been stolen… Read More “Stolen Levemir Warning”
According to research presented at the American Diabetes Association’s 69th Scientific Sessions, using rosiglitazone (brand name Avandia) in combination with metformin or a sulfonylurea does not increase the risk for cardiovascular disease or death in people with Type 2 diabetes. But some scientists have met these results critically, claiming that the study does not have enough statistical power to resolve any of the controversy surrounding this drug. Read More “Research on Rosiglitazone”
Recent data analysis by researchers at the University of Cambridge suggests that tight blood glucose control in people with Type 2 diabetes can reduce the risk of cardiovascular events by as much as 17%, addressing some of the controversy raised by previous research such as the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the Action in Diabetes and Vascular Disease (ADVANCE) study, and the Veterans Affairs Diabetes Trial (VADT)…
A routine blood test for triglycerides, used as a screening tool to determine whether a person is at risk of developing cardiovascular disease, may also be a useful predictor of nerve damage, according to a recent study in the journal Diabetes…
Before moving on to this week’s story, I’d like to take just a moment to introduce myself. After working as an editor at Diabetes Self-Management magazine for nearly six years, I’m taking over at the helm of the Web site. I’m extremely excited to begin my tenure as Web Editor and look forward to learning more about you through your comments and e-mails. And now, to the news…
